Isracann Biosciences Inc. (ISCNF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 0.19: the stock has moved about 81% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerIsracann Biosciences Inc. (ISCNF) trades at $0.00001. Isracann Biosciences Inc. cultivates and distributes medical cannabis in Israel, exporting products to Germany and developing cultivation facilities. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for ISCNF: ISCNF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Isracann Biosciences Inc. (ISCNF) Healthcare & Pipeline Overview
Isracann Biosciences Inc. focuses on the cultivation and distribution of medical cannabis within Israel, with exports to Germany. Operating in the Drug Manufacturers - Specialty & Generic industry, the company develops cultivation facilities to support its operations and navigate the evolving regulatory environment of the medical cannabis market.
What Is the Investment Thesis for ISCNF?
Isracann Biosciences Inc. presents a speculative investment opportunity within the evolving medical cannabis market. The company's focus on cultivation and distribution in Israel, coupled with exports to Germany, offers exposure to growing markets. However, the company's market capitalization of $0.00B and negative P/E ratio of -0.47 indicate financial challenges. Potential investors should carefully consider the risks associated with OTC-listed companies, including liquidity and disclosure requirements. Growth catalysts include expansion of cultivation facilities and increased market penetration in Germany. The company's beta of 0.19 suggests lower volatility compared to the overall market.
Based on FMP financials and quantitative analysis
ISCNF Key Highlights
Market capitalization of $0.00B, reflecting the company's small size and potential for growth or volatility.
- Negative P/E ratio of -0.47, indicating that the company is currently not profitable.
- Beta of 0.19, suggesting the stock is less volatile than the overall market.
- Focus on the medical cannabis market in Israel, a region with evolving regulations and increasing demand.
- Exports to Germany, providing access to a larger and more established market for medical cannabis.
Who Are ISCNF's Competitors?
ISCNF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AVCNF Avicanna Inc. | $0.07 | -1.28% | $8.93M | — |
| CWBHF Charlotte's Web Holdings, Inc. | $0.27 | +1.83% | $73.1M | — |
| TAK Takeda Pharmaceutical Company Limited | $17.81 | -0.31% | $56.8B | 64 5-pillar |
| TEVA Teva Pharmaceutical Industries Limited | $39.66 | +0.33% | $46.2B | 66 5-pillar |
| HLN Haleon plc | $8.82 | +0.23% | $38.8B | 78 5-pillar |
| ZTS Zoetis Inc. | $71.41 | +2.47% | $29.2B | 87 5-pillar |
| VTRS Viatris Inc. | $17.62 | +0.11% | $20.5B | 32 5-pillar |
| ELAN Elanco Animal Health Incorporated | $22.51 | +1.67% | $11.2B | 33 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ISCNF's Key Strengths?
Cultivation and distribution expertise in Israel.
- Export agreements to Germany.
- Development of cultivation facilities.
- Focus on the medical cannabis market.
What Are ISCNF's Weaknesses?
Small market capitalization.
- Negative P/E ratio.
- Limited financial resources.
- Dependence on regulatory approvals.
What Are the Key Risks for ISCNF?
Financial-distress signal — its Altman Z-Score of -30.66 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Evolving regulations in the cannabis industry could negatively impact operations.
- Competition from established pharmaceutical companies and other cannabis producers.
- Limited financial resources may hinder growth initiatives.
- Dependence on regulatory approvals for cultivation and distribution.
What Are ISCNF's Competitive Advantages?
- Established cultivation facilities in Israel.
- Distribution network in Israel.
- Export agreements with distributors in Germany.
- Expertise in cultivating medical cannabis.
What Does ISCNF Do?
Isracann Biosciences Inc., established in 2010 and headquartered in Vancouver, Canada, is dedicated to the cultivation and distribution of medical cannabis, primarily within Israel. Originally named Atlas Blockchain Group Inc., the company rebranded in October 2019 to reflect its focus on the burgeoning cannabis industry. Isracann develops cultivation facilities to ensure a consistent and high-quality supply of medical cannabis. The company also exports its products to Germany, expanding its market reach beyond Israel. Isracann operates in a sector characterized by evolving regulations and increasing demand for medical cannabis products. The company's strategic focus on cultivation and distribution positions it to capitalize on the expanding market for medical cannabis in both Israel and Europe.
What Products and Services Does ISCNF Offer?
- Cultivates medical cannabis in Israel.
- Distributes medical cannabis products.
- Develops cultivation facilities to increase production capacity.
- Exports medical cannabis products to Germany.
- Focuses on the medical cannabis market.
- Adapts to evolving regulations in the cannabis industry.
How Does ISCNF Make Money?
- Cultivation of medical cannabis.
- Distribution of cannabis products to pharmacies and distributors.
- Export of cannabis products to international markets.
- Revenue generation through sales of medical cannabis products.
What Industry Does ISCNF Operate In?
Isracann Biosciences Inc. operates within the Drug Manufacturers - Specialty & Generic industry, specifically targeting the medical cannabis market. This sector is characterized by rapid growth, evolving regulations, and increasing acceptance of cannabis for medical purposes. The competitive landscape includes both established pharmaceutical companies and emerging cannabis producers. Isracann's focus on cultivation and distribution in Israel positions it to capitalize on the local market, while exports to Germany provide access to a larger European market. The industry is subject to regulatory changes and market fluctuations, requiring companies to adapt to evolving conditions.
Who Are ISCNF's Key Customers?
- Patients requiring medical cannabis for various conditions.
- Pharmacies and distributors in Israel.
- Pharmacies and distributors in Germany.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Financial Health
Isracann Biosciences Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -30.66 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Its free cash flow yield is -66.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.38 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Isracann Biosciences Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Vancouver, CA. The company is led by CEO Ajay Singh Kaila. ISCNF has traded publicly since 2017.
ISCNF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
ISCNF Latest News
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
ISCNF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ISCNF.
Price Targets
Wall Street price target analysis for ISCNF.
ISCNF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for ISCNF; grades run from A+ (80-100) to F (below 30).
Leadership: Ajay Singh Kaila
CEO
Ajay Singh Kaila serves as the CEO of Isracann Biosciences Inc. His background includes experience in corporate management and strategic development. Prior to joining Isracann, Kaila held various leadership positions in the technology and resource sectors, focusing on driving growth and innovation. He brings a track record of successfully navigating complex regulatory environments and building strong teams. Kaila's expertise in strategic planning and execution is expected to guide Isracann through its next phase of growth in the medical cannabis market.
Track Record: Since assuming the role of CEO, Ajay Singh Kaila has focused on expanding Isracann's cultivation capacity and strengthening its distribution network. He has overseen the development of new cultivation facilities and the expansion of the company's export operations to Germany. Kaila has also prioritized building relationships with key stakeholders in the medical cannabis industry, including regulators, distributors, and researchers.
ISCNF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Isracann Biosciences Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB, or major exchanges like NYSE or NASDAQ. Companies in this tier may have limited trading volume and liquidity. Investing in companies on the OTC Other tier carries significant risks due to the potential for limited information and regulatory oversight compared to companies listed on major exchanges.
- OTC Tier: OTC Other
- Limited liquidity due to OTC Other listing.
- Lack of regulatory oversight compared to major exchanges.
- Potential for limited financial disclosure.
- Higher volatility due to low trading volume.
- Increased risk of fraud or manipulation.
- Verify the company's financial reporting practices.
- Obtain and review audited financial statements.
- Assess the company's management team and their experience.
- Research the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Company has been in operation since 2010.
- Focus on the medical cannabis market.
- Exports to Germany.
- Development of cultivation facilities.
What Investors Ask About Isracann Biosciences Inc. (ISCNF) — Healthcare
What do analysts say about ISCNF stock?
As of 2026-03-16, there is no available analyst coverage or consensus for ISCNF stock. The company's small market capitalization and OTC listing may limit analyst interest. Investors should conduct their own thorough research and consider the risks associated with investing in OTC-listed companies.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available for OTC-listed companies.
- Financial data may not be readily available or audited.